ImmuCell (ICCC) grants VP Bobbi Jo Brockmann 100,000 stock options

Rhea-AI Filing Summary

ImmuCell Corporation filed a Form 4 showing an option grant to executive and director Bobbi Jo Brockmann. On January 27, 2026, she received stock options to purchase 100,000 shares of common stock at an exercise price of $6.265 per share, expiring on January 27, 2036.

The options were granted in connection with her role as Vice President of Sales and Marketing. They vest over three years: 33,333 shares become exercisable on each of January 27, 2027 and January 27, 2028, and 33,334 shares become exercisable on January 27, 2029. Following this grant, she beneficially owns 100,000 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Brockmann Bobbi Jo

Role VP of Sales and Marketing

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy)	100,000	$0.00	--

Holdings After Transaction: Stock Options (right to buy) — 100,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brockmann Bobbi Jo

(Last) (First) (Middle)

C/O IMMUCELL CORPORATION

56 EVERGREEN DRIVE

(Street)

PORTLAND ME 04103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IMMUCELL CORP /DE/ [ ICCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP of Sales and Marketing

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$6.265	01/27/2026		A		100,000		(1)	01/27/2036	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. Option grant made to Ms. Brockmann in connection with her employment as Vice President of Sales and Marketing. The option shall be treated as an incentive stock option to the maximum extent permitted by the Internal Revenue Code of 1986, as amended, with the balance treated as a nonqualified stock option. The stock option vests as follows: 33,333 shares becoming exercisable on each of January 27, 2027 and January 27, 2028 and 33,334 shares becoming exercisable on January 27, 2029.

	/s/ Timothy C. Fiori Attorney-in-Fact	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ImmuCell (ICCC) report for Bobbi Jo Brockmann?

ImmuCell reported that Bobbi Jo Brockmann received stock options to buy 100,000 common shares. The options were granted on January 27, 2026 as part of her role, giving her the right to purchase shares at a fixed exercise price through January 27, 2036.

How many ImmuCell (ICCC) stock options were granted to Bobbi Jo Brockmann and at what price?

Bobbi Jo Brockmann was granted 100,000 ImmuCell stock options. Each option has an exercise price of $6.265 per share, meaning she can buy up to 100,000 shares at that price once the options vest, through their January 27, 2036 expiration.

What is the vesting schedule of Bobbi Jo Brockmann’s ImmuCell (ICCC) stock options?

The 100,000 ImmuCell stock options vest in three annual tranches. 33,333 options become exercisable on January 27, 2027, another 33,333 on January 27, 2028, and the remaining 33,334 on January 27, 2029, creating a gradual three-year vesting timeline.

What role does Bobbi Jo Brockmann hold at ImmuCell (ICCC) related to this option grant?

Bobbi Jo Brockmann serves as ImmuCell’s Vice President of Sales and Marketing and is also a director. The Form 4 states the 100,000 stock options were granted in connection with her employment in this executive role, reflecting part of her overall compensation package.

How are Bobbi Jo Brockmann’s ImmuCell (ICCC) options classified for tax purposes?

The filing states the option will be treated as an incentive stock option to the maximum extent allowed under the Internal Revenue Code of 1986, as amended. Any remaining portion that does not qualify will be treated as a nonqualified stock option for tax purposes.

How many ImmuCell (ICCC) derivative securities does Bobbi Jo Brockmann own after this transaction?

After the January 27, 2026 grant, Bobbi Jo Brockmann beneficially owns 100,000 derivative securities in ImmuCell. These are the stock options reported, held directly in her name, each representing the right to purchase one share of ImmuCell common stock upon exercise.